← Back to Analyst Consensus 
GENB Buy
Generate Biomedicines, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 8, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 28, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 14, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| May 8, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 13, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Mar 24, 2026 | Goldman Sachs | initiate | — → Buy | — | 54% |
| Mar 24, 2026 | Morgan Stanley | initiate | — → Overweight | — | 54% |
| Mar 24, 2026 | Piper Sandler | initiate | — → Overweight | — | 54% |
| Mar 24, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Mar 24, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
Price Target Trend
Jul 18, 2026 Oct 27, 2026
EPS Estimates
+1q —
0y —
0q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days